1. Nickel-chromium-aluminum-iron alloy having (in wt.-%) 12 to 28% chromium, 1.8 to 3.0% aluminum, 1.0 to 15% iron, 0.01 to 0.5% silicon, 0.005 to 0.5% manganese, 0.01 to 0.20% yttrium, 0.02 to 0.60% titanium, 0.01 to 0.2% zirconium, 0.0002 to 0.05% magnesium, 0.0001 to 0.05% calcium, 0.03 to 0.11% carbon, 0.003 to 0.05% nitrogen, 0.0005 to 0.008% boron, 0.0001-0.1010% oxygen, 0.001 to 0.030% phosphorus, max. 0.010% sulfur, max. 0.5% molybdenum, max. 0.5% tungsten, remainder nickel and the usual process-related contaminants, wherein the following relationships must be fulfilled:
0<7.7C\u2212x\xb7a<1.0\u2003\u2003(2)
with a=PN, if PN>0\u2003\u2003(3a)
or a=0, if PN\u22660\u2003\u2003(3b)
and x=(1.0Ti+1.06Zr)(0.251Ti+0.132Zr)\u2003\u2003(3c)
where PN=0.251Ti+0.132Zr\u22120.857N\u2003\u2003(4)
and Ti, Zr, N, C are the concentration of the related elements in mass-%.
2. Alloy according to claim 1, having a chromium content of 16 to 28%.
3. Alloy according to claim 1, having a chromium content of 20 to 28%.
4. Alloy according to claim 1, having an aluminum content of 1.9 to 2.9%.
5. Alloy according to claim 1, having an iron content of 1.0 to 11.0%.
6. Alloy according to claim 1, having a silicon content of 0.01-0.2%, particularly 0.01 to <0.10%.
7. Alloy according to claim 1, having a manganese content of 0.005 to 0.20%.
8. Alloy according to claim 1, having an yttrium content of 0.01 to <0.045%.
9. Alloy according to claim 1, in which yttrium is completely or partially replaced by 0.001 to 0.2% lanthanum andor by 0.001 to 0.2% cerium.
10. Alloy according to claim 1, in which titanium is completely or partially replaced by 0.001 to 0.6% niobium.
11. Alloy according to claim 1, in which zirconium is completely or partially substituted by 0.001 to 0.2% hafnium and the formulas 3c and 4 are replaced by the following formulas:
x=(1.0Ti+1.06Zr+0.605Hf)(0.251*Ti+0.132Zr+0.0672Hf)\u2003\u2003(3c-1)
where PN=0.251Ti+0.132Zr+0.0672Hf\u22120.857N\u2003\u2003(4-1)
and Ti, Zr, Hf, N, C are the concentration of the elements in question in mass-%.
12. Alloy according to claim 1, having a magnesium content of 0.0005 to 0.03%.
13. Alloy according to claim 1, having a calcium content of 0.0005 to 0.02%.
14. Alloy according to claim 1, having a carbon content of 0.04 to 0.10%.
15. Alloy according to claim 1, having a nitrogen content of 0.005 to 0.04%.
16. Alloy according to claim 1, furthermore containing up to 5.0% Co.
17. Alloy according to claim 1, furthermore containing maximally 0.1% vanadium.
18. Alloy according to claim 1, wherein the contaminants are adjusted in contents of max. 0.5% Cu, max. 0.002% Pb, max. 0.002% Zn, max. 0.002% Sn.
19. Use of the alloy according to claim 1 as a strip, sheet, wire, rod, pipe welded with a longitudinal seam, and seamless pipe.
20. Use of the alloy according to claim 1 for the production of deep-drawn parts from strip, wire, or sheet.
21. Use of the alloy according to claim 1 for the production of seamless pipe from rod-shaped materials.
22. Use of the alloy according to claim 1 in furnace construction, for example as muffles, furnace rollers, or support frames.
23. Use of the alloy according to claim 1 as a mantle for glow plugs, in exhaust gas systems, as a catalytic converter support foil.
24. Use of the alloy according to claim 1 as a pipe in the petrochemical industry.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition, in the form of capsules, tablets, or injectable solutions or suspensions, for use as a pharmaceutical in the treatment of a psychotic disorder in a human consisting essentially of an antipsychotic effective amount of (S)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier or diluent.
2. The pharmaceutical composition of claim 1 for treating a psychotic disorder in a human consisting essentially of an antipsychotic effective amount of (S)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol prepared by enantioselective reduction of iloperidone and a pharmaceutical carrier or diluent.
3. The pharmaceutical composition of claim 2, wherein the reduction is effected by contact of iloperidone with an optically-active borane complex of formula IV
4. The pharmaceutical composition of claim 1 in the form of a capsule or tablet.
5. The pharmaceutical composition of claim 1 in the form of a capsule, tablet, or injectable solution or suspension consisting essentially of about 1 to about 500 mg of (S)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol and a pharmaceutical carrier or diluent.
6. The pharmaceutical composition of claim 1 in unit dosage form consisting essentially of 0.25 to about 25 mg of (S)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3yl)-piperidin-1-ylpropoxyl}-3-methoxy-phenyl-ethanol and a pharmaceutical carrier or diluent.
7. A method for treating a psychotic disorder in a human subject in need of such treatment, the method comprising orally or parenterally administering to the subject a therapeutically effective amount of (S)-1-4-{3-4-(6-fluoro-benzold(d)isoxazol-3-yl)-piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol or a pharmaceutically acceptable salt thereof admixed with at least one pharmaceutical carrier.
8. The method of claim 7, wherein the pharmaceutical composition is in the form of a capsule or tablet.
9. The method of claim 7, wherein the pharmaceutical composition is in the form of a capsule, tablet, or injectable solution or suspension consisting essentially of about 1 to about 500 mg of (S)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3-yl)piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol and a pharmaceutical carrier or diluent.
10. The method of claim 7, wherein the pharmaceutical composition is in unit dosage form consisting essentially of 0.25 to about 25 mg of (s)-1-4-{3-4-(6-fluoro-benzo(d)isoxazol-3-yl)-piperidin-1-ylpropoxy}-3-methoxy-phenyl-ethanol and a pharmaceutical carrier or diluent.